StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines Upfront License & Development Milestone Fees by Quarter

Upfront License & Development Milestone Fees ($M) ($M)

QuarterlyAnnual

BeOne Medicines Upfront License & Development Milestone Fees: $23.3M in Q2 2026, up 13.7% from a year earlier.

Latest, Q2 2026
23.3
Period ended Jun 30, 2026
Change on a year earlier
+13.7%
20.5 in Q2 2025
History
24 quarters
Since Q1 2019
Sources
16
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Collaborative Arrangements Note (XBRL) & MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUpfront License & Development Milestone Fees ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202623.3+13.7%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20260.50–Form 10-Q (filed 2026-05-06) ↗
Q4 2025Dec 31, 20250-100.0%Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 30, 20250.20-96.0%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 202520.5+78.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20250-100.0%Form 10-Q (filed 2026-05-06) ↗
Q4 2024Dec 31, 202462.5+66.2%Form 10-K (filed 2026-02-26) ↗
Q3 2024Sep 30, 20245-79.5%Form 10-Q (filed 2025-11-06) ↗
Q2 2024Jun 30, 202411.5–Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 202435–Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 202337.6-30.6%Form 10-K (filed 2026-02-26) ↗
Q3 2023Sep 30, 202324.4+22.0%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 202254.2–Form 10-K (filed 2025-02-27) ↗
Q3 2022Sep 30, 202220–Form 10-Q (filed 2023-11-09) ↗

Breakdown

What makes up upfront License & Development Milestone Fees

Cite this data

StockData. (2026). BeOne Medicines Upfront License & Development Milestone Fees ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-upfront-milestone-tot

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.